Patents by Inventor Gabriel Galvin

Gabriel Galvin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOTOPICALLY LABELED BILE ACID DERIVATIVES
    Publication number: 20230057232
    Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof
    Type: Application
    Filed: September 7, 2022
    Publication date: February 23, 2023
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Gabriel GALVIN, Kevin SCHAAB, Matthew YANIK
  • Isotopically labeled bile acid derivatives
    Patent number: 11472831
    Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 18, 2022
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Gabriel Galvin, Kevin Schaab, Mathew Yanik
  • METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES
    Publication number: 20220127302
    Abstract: The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof.
    Type: Application
    Filed: June 8, 2021
    Publication date: April 28, 2022
    Inventors: Roberto PELLICCIARI, Antimo GIOIELLO, Gabriel GALVIN, Ronald D. LEWIS, II, Mathew YANIK, Myoung Goo KIM, Frederik Ronald LEUSINK, Bartjan KONING, Thomas HENSEL
  • Methods and intermediates for the preparation of bile acid derivatives
    Patent number: 11066437
    Abstract: The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof, comprising the step of reacting a compound of formula I-4 with a halogenating reagent to provide a compound of formula I-5a
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: July 20, 2021
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello, Gabriel Galvin, Ronald D. Lewis, II, Mathew Yanik, Myoung Goo Kim, Frederik Ronald Leusink, Bartjan Koning, Thomas Hensel
  • ISOTOPICALLY LABELED BILE ACID DERIVATIVES
    Publication number: 20200165290
    Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.
    Type: Application
    Filed: July 23, 2018
    Publication date: May 28, 2020
    Inventors: Gabriel GALVIN, Kevin SCHAAB, Mathew YANIK
  • METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES
    Publication number: 20180371009
    Abstract: The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 27, 2018
    Inventors: Roberto Pellicciari, Antimo Gioiello, Gabriel Galvin, Ronald D Lewis, Mathew Yanik, Myoung Goo Kim, Fred Leusink, Bartjan Koning, Thomas Hensel
  • MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID
    Publication number: 20160214947
    Abstract: Described herein are certain processes for the synthesis of compounds of Formula (I):
    Type: Application
    Filed: February 19, 2016
    Publication date: July 28, 2016
    Inventors: Esmir GUNIC, Gabriel GALVIN
  • Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
    Patent number: 9296709
    Abstract: Described herein are certain processes for the synthesis of compounds of Formula (I):
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: March 29, 2016
    Assignee: ARDEA BIOSCIENCES, INC.
    Inventors: Esmir Gunic, Gabriel Galvin
  • MANUFACTURE OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID
    Publication number: 20150252010
    Abstract: Described herein are certain processes for the synthesis of compounds of Formula (I):
    Type: Application
    Filed: July 2, 2013
    Publication date: September 10, 2015
    Inventors: Esmir Gunic, Gabriel Galvin
  • POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF
    Publication number: 20130345271
    Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.
    Type: Application
    Filed: July 30, 2013
    Publication date: December 26, 2013
    Applicant: Ardea Biosciences, Inc.
    Inventors: Irina ZAMANSKY, Gabriel GALVIN, Jean-Luc GIRARDET
  • Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
    Patent number: 8546436
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: October 1, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Laszlo R. Treiber, Gabriel Galvin, Irina Zamansky, Jean-Luc Girardet
  • Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4-1,2,4-triazol-3-ylthio) acetate, and uses thereof
    Patent number: 8524754
    Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: September 3, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Irina Zamansky, Jean-Luc Girardet, Gabriel Galvin
  • Methods for synthesizing heterocyclic compounds
    Patent number: 8222413
    Abstract: A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reacted in a solvent that comprises water in an amount greater than 50 percent by volume based on the amount of the solvent and/or are reacted in a solvent that comprises an organic solvent component that has a boiling point of greater than 100° C. at atmospheric pressure.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Gabriel Galvin, Eric Harwood, David Ryckman, Shuguang Zhu
  • POLYMORPHIC FORMS OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND USES THEREOF
    Publication number: 20120172405
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Application
    Filed: December 28, 2011
    Publication date: July 5, 2012
    Applicant: Ardea Biosciences Inc.
    Inventors: Gabriel Galvin, Laszlo R. Treiber, Irina Zamansky, Jean-Luc Girardet
  • POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF
    Publication number: 20120129903
    Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.
    Type: Application
    Filed: January 5, 2011
    Publication date: May 24, 2012
    Applicant: Ardea Biosciences, Inc.
    Inventors: Irina Zamansky, Jean-Luc Girardet, Gabriel Galvin
  • METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS.
    Publication number: 20110046376
    Abstract: A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reacted in a solvent that comprises water in an amount greater than 50 percent by volume based on the amount of the solvent and/or are reacted in a solvent that comprises an organic solvent component that has a boiling point of greater than 100° C. at atmospheric pressure.
    Type: Application
    Filed: May 17, 2006
    Publication date: February 24, 2011
    Applicant: NOVARTIS AG
    Inventors: Gabriel Galvin, Eric Harwood, David Ryckman, Shuguang Zhu
  • Methods for the Preparation, Isolation and Purification of Epothilone B, and X-Ray Crystal Structures of Epothilone B
    Publication number: 20070122891
    Abstract: The present invention relates to improved methods for the production, isolation and purification of epothilone B. These methods include, for example, a fermentation process for the production of epothilone B, isolation via adsorption onto a resin, and subsequent purification.
    Type: Application
    Filed: January 31, 2007
    Publication date: May 31, 2007
    Inventors: Daniel Benigni, Robert Stankavage, Shu-Jen Chiang, Hsing Hou, Bruce Eagan, Dennis Gu, David Hou, Les Mintzmyer, Thomas Tully, Brian Davis, Ivan Hargro, Mark Mascari, Gabriel Galvin, Gregory Stein, Cary McConlogue, Fahri Comezoglu
  • PROCESS FOR PREPARING A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND INTERMEDIATES EMPLOYED THEREIN
    Publication number: 20070123579
    Abstract: A process is provided for preparing a dipeptidyl peptidase IV inhibitor of the structure is treated with TFAA in isopropyl acetate to protect the tertiary hydroxyl group as a trifluoroacetate group to form 4 which is converted to acid chloride compound 5 (which is a novel compound) using Vilsmeier reagent or other chloro reagent and coupled with compound 6 in a heterogeneous mixture of ethyl acetate and aqueous bicarbonate to give compound 7 The N,O-bis(trifluoroacetyl) groups of compound 7 are deprotected to give free base compound 10.
    Type: Application
    Filed: January 30, 2007
    Publication date: May 31, 2007
    Inventors: Padam Sharma, Edward Gublo, Gabriel Galvin, Susan Boettger, Saibaba Racha
  • Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
    Patent number: 7172884
    Abstract: The present invention relates to improved methods for the production, isolation and purification of epothilone B. These methods include, for example, a fermentation process for the production of epothilone B, isolation via adsorption onto a resin, and subsequent purification.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel Benigni, Robert Stankavage, Shu-Jen Chiang, Hsing Hou, Bruce Eagan, Dennis Gu, David Hou, Les Mintzmyer, Thomas P. Tully, Brian L. Davis, Ivan Hargro, Mark Mascari, Gabriel Galvin, Gregory Stein, Cary W. McConlogue, Fahri T. Comezoglu
  • Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
    Publication number: 20060035954
    Abstract: A process is provided for preparing the intermediate A in accordance with the following reaction sequence The intermediate A is used in preparing DPP IV inhibitors which are useful in treating diabetes.
    Type: Application
    Filed: August 8, 2005
    Publication date: February 16, 2006
    Inventors: Padam Sharma, Gabriel Galvin, Susan Boettger, Saibaba Racha, Jingyang Zhu, Jack Melton, Boguslaw Mudryk